Stockscreener 앱 받기
63.54
2.38%
-1.55
시간 외 거래:
63.54
전일 마감가:
$65.09
열려 있는:
$65.9
하루 거래량:
1.21M
Relative Volume:
1.46
시가총액:
$6.66B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
50.43
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-12.62%
1개월 성능:
+3.98%
6개월 성능:
+84.55%
1년 성능:
+193.35%
1일 변동 폭
$63.19
$66.48
1주일 범위
$63.19
$75.00
52주 변동 폭
$20.84
$75.00
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
63.54 | 6.66B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Blue Trust Inc. Sells 8,728 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Van ECK Associates Corp Purchases New Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Reaches New 12-Month HighWhat's Next? - MarketBeat
Corcept stock down on California lawsuit (CORT:NASDAQ) - Seeking Alpha
Corcept Therapeutics stock soars to all-time high of $71.3 - MSN
New York State Teachers Retirement System Acquires 3,789 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
New York State Teachers Retirement System Purchases 3,789 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Roman Butler Fullerton & Co. Grows Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Big health insurers sue Peninsula company over its lone drug - The Business Journals
Corcept Therapeutics stock soars to all-time high of $62.34 - MSN
Van ECK Associates Corp Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Allspring Global Investments Holdings LLC Has $10.60 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Abortion Drugs Market Generated Opportunities, Future Scope - openPR
Braun Stacey Associates Inc. Invests $14.94 Million in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Certuity LLC Takes $204,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
HC Wainwright Has Optimistic Outlook of CORT Q1 Earnings - MarketBeat
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics (NASDAQ:CORT) Hits New 1-Year HighHere's Why - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. Sells 2,200 Shares - MarketBeat
At Corcept Therapeutics, Hazel Hunt Chooses To Exercise Options, Resulting In $10.61M - Benzinga
H.C. Wainwright lifts Corcept stock target to $115 on drug outlook - MSN
Corcept therapeutics director sells shares worth $149,776 - MSN
Corcept therapeutics director Daniel Swisher sells shares worth $149,776 By Investing.com - Investing.com South Africa
Yousif Capital Management LLC Sells 516 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept therapeutics director sells shares worth $149,776 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells shares worth $149,776 - MSN
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call - Yahoo Finance
Research Analysts Issue Forecasts for CORT FY2029 Earnings - MarketBeat
abrdn plc Has $21.97 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Corcept Therapeutics (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics’ (CORT) “Buy” Rating Reiterated at HC Wainwright - Defense World
Calamos Advisors LLC Sells 4,908 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Boston Trust Walden Corp Lowers Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
H.C. Wainwright maintains $80 target on Corcept Therapeutics stock - MSN
Corcept Therapeutics Inc (CORT) Stock Sees a-0.60 Decrease - The News Heater
H.C. Wainwright maintains $80 target on Corcept Therapeutics stock By Investing.com - Investing.com UK
Q3 EPS Forecast for Corcept Therapeutics Raised by Analyst - MarketBeat
Endogenous Cushing's Syndrome Market Statistics Expected - openPR
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):